Results 61 to 70 of about 74,999 (298)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Acute Alcoholic Hepatitis

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2017
Objective: To examine the natural history of acute alcoholic hepatitis (AH) and identify predictors of mortality for AH using data from a prospective multicenter observational study.
Spencer Lourens, PhD, Dharma B. Sunjaya, MD, Ashwani Singal, MD, Suthat Liangpunsakul, MD, MPH, Puneet Puri, MD, Arun Sanyal, MD, Xiaowei Ren, MS, Gregory J. Gores, MD, Svetlana Radaeva, PhD, Naga Chalasani, MD, David W. Crabb, MD, Barry Katz, PhD, Patrick S. Kamath, MD, Vijay H. Shah, MD, David Crabb, MD, Naga Chalasani, MD, Suthat Liangpunsakul, MD, Barry Katz, PhD, Spencer Lourens, PhD, Andy Borst, BS, Ryan Cook, MPH, Andy Qigui Yu, PhD, David Nelson, PhD, Romil Saxena, MD, Sherrie Cummings, RN, Megan Comerford, BS, Lakye Edwards, BS, Vijay H. Shah, MD, Gregory Gores, MD, Patrick S. Kamath, MD, Vikas Verma, PhD, Sarah Wilder, RN, BSN, Amy Olofson, RN, Amanda Schimek, Arun Sanyal, MD, Puneet Puri, MD, Susan Walker, RN, MSN, Svetlana Radaeva, PhD, Andras Orosz, PhD   +38 more
doaj   +1 more source

Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis

Metabolites, 2022
Alcoholic hepatitis is a major health care burden in the United States due to significant morbidity and mortality. Early identification of patients with alcoholic hepatitis at greatest risk of death is extremely important for proper treatments and ...
Bei Gao, Tsung-Chin Wu, Sonja Lang, Lu Jiang, Yi Duan, Derrick E. Fouts, Xinlian Zhang, Xin-Ming Tu, Bernd Schnabl   +8 more
doaj   +1 more source

Early liver transplantation for severe alcoholic hepatitis [PDF]

, 2018
Purpose of reviewAlcohol-related liver disease is now the most common indication for liver transplant in the United States. Acute alcoholic hepatitis represents a subpopulation with short-term mortality approaching 70% in severe cases - these patients ...
Brian P. Lee, Lee, Brian P, Norah A. Terrault, Terrault, Norah A   +3 more
core   +1 more source

Fibrates Inhibit PLTP‐induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs

Advanced Science, EarlyView.
Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang, Yaning Li, Jianxun Cai, Lisi Luo, Pengfei Yang, Yutong Chen, Jiancong Zhou, Yan Zeng, Jiaping Yu, Weiyu Zhang, Wenzheng Pang, Yufang Li, Chunhua Wen, Jian Li, Linjuan Zeng   +14 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases

Regulatory Mechanisms in Biosystems, 2021
Non-alcoholic fatty liver disease is an important cause of global liver disease characterized by diffuse hepatocytes with hepatocellular ballooning, intrahepatic inflammation and progressive fibrosis.
V. I. Didenko, I. A. Klenina, О. M. Tatarchuk, O. I. Hrabovska, O. P. Petishko   +4 more
doaj   +1 more source

Letter to the Editor: Glucocorticosteroids for alcoholic for alcoholic hepatitis

, 2020
Our Cochrane systematic review on glucocorticosteroids versus placebo or no intervention for people with alcoholic hepatitis found no evidence of a difference on clinically important outcomes at either of the three timepoints of follow-up.(4) Our review (
Giovanni Casazza, Nikolova, Dimitrinka, Gluud, Christian, Casazza, Giovanni, Daria L. Varganova, Chavdar S. Pavlov, Dimitrinka Nikolova, Pavlov, Chavdar S, Varganova, Daria, Christian Gluud   +9 more
core   +1 more source

Genomics and metabonomics in severe alcoholic hepatitis [PDF]

, 2019
Severe alcoholic hepatitis is a florid presentation of alcohol-related liver disease and is associated with very high short-term mortality, in excess of 20% within 28 days.
Atkinson, Stephen
core   +1 more source

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

Advanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang, Dandan Zong, Rui Liu, Yubo Wang, Qingqing Gu, Yao Yao, Wenfang Zheng, Mengmeng Yuan, Simeng Wang, Rongrong Cui, Daxu Li, Siwen Dang, Peng Hou   +12 more
wiley   +1 more source